Biotech
Singapore’s biotech strategy will benefit from collective, not competitive, thinking
Successful innovation requires a holistic risk-based approach beyond financial, infrastructure and manpower investments
Novartis strikes deal with UK biotech for up to US$1.7 billion
Novartis is on a deal spree this year, including the US$12 billion acquisition of Avidity Biosciences
Forget chasing the next Pfizer: Singapore’s biotech future lies in innovation, not giants
The Republic may not have a major player to call its own, but licensing deals and early-stage breakthroughs can still count as wins
Redefining industries through innovation and insight
These Emerging Enterprise Awards finalists are applying technology and data to make businesses more efficient and improve lives
Novartis agrees to buy Avidity in US$12 billion biotech deal
The full deal is expected to close in the first half of 2026, subject to the completion of the separation
Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue
After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client
Challenging economic conditions raise the bar for nascent biotech startups as funding dries up
The pullback in science and tech funding in the US has cooled investor sentiment for now, but observers say more money may eventually flow into Asia and Europe
Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off
Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term outlook is unlikely to change
China’s biotech boom: Collaboration, not competition, for Singapore
While China dominates global drug development, Singapore’s strength lies in bridging Asian innovation with Western capital, say industry players
The biopharma scene in Singapore is vibrant, but few make it to SGX
More listings will keep the Republic’s capital markets robust, develop an ecosystem and strengthen its regional hub status
